Edmond DE Rothschild Holding S.A. Acquires 9,700 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH)

Edmond DE Rothschild Holding S.A. raised its holdings in shares of SOPHiA GENETICS SA (NASDAQ:SOPH) by 5.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 203,334 shares of the company’s stock after acquiring an additional 9,700 shares during the quarter. Edmond DE Rothschild Holding S.A. owned approximately 0.31% of SOPHiA GENETICS worth $1,002,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in SOPH. Essex Investment Management Co. LLC grew its stake in shares of SOPHiA GENETICS by 112.1% in the first quarter. Essex Investment Management Co. LLC now owns 262,834 shares of the company’s stock valued at $1,296,000 after buying an additional 138,933 shares in the last quarter. Moloney Securities Asset Management LLC boosted its position in SOPHiA GENETICS by 111.4% during the first quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock worth $878,000 after purchasing an additional 93,800 shares during the period. Legato Capital Management LLC bought a new position in SOPHiA GENETICS during the fourth quarter worth $235,000. Principal Financial Group Inc. boosted its position in SOPHiA GENETICS by 2.6% during the fourth quarter. Principal Financial Group Inc. now owns 995,500 shares of the company’s stock worth $4,689,000 after purchasing an additional 24,837 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in SOPHiA GENETICS by 90.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,834 shares of the company’s stock worth $65,000 after purchasing an additional 6,552 shares during the period. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Stock Up 1.1 %

Shares of SOPH traded up $0.05 during midday trading on Thursday, reaching $4.76. 4,248 shares of the stock were exchanged, compared to its average volume of 79,408. SOPHiA GENETICS SA has a twelve month low of $2.13 and a twelve month high of $7.37. The stock’s 50 day simple moving average is $4.76 and its 200 day simple moving average is $4.83.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. The business had revenue of $15.78 million during the quarter, compared to the consensus estimate of $16.80 million. SOPHiA GENETICS had a negative return on equity of 47.56% and a negative net margin of 113.71%. On average, equities analysts expect that SOPHiA GENETICS SA will post -1.04 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Guggenheim began coverage on shares of SOPHiA GENETICS in a research report on Thursday, June 27th. They set a “buy” rating and a $6.00 price objective for the company.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.